In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Argenx Se (ARGX), with a price target of $144. The company’s shares opened today at $132.03, close to its 52-week high of $135.46.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 25.7% and a 50.0% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Clementia Pharmaceuticals Inc, Kiniksa Pharmaceuticals Ltd, and Voyager Therapeutics Inc.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $148, a 12.1% upside from current levels. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $157 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $135.46 and a one-year low of $63.81. Currently, Argenx Se has an average volume of 217.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.
